Targeting Gastric Cancer Cells using Nanoparticles to Improve Diagnosis and Treatment Outcomes while Minimizing Off-Target Toxicity
DOI:
https://doi.org/10.47611/jsrhs.v12i1.4459Keywords:
Nanoparticles, Gastric Cancer, Translational Medicine, Disease Detection and Diagnosis, Disease Treatment and Therapies, Chemotherapy, Targeted Drug Delivery, Nanotechnology in MedicineAbstract
Conventional treatments for metastatic and unresectable gastric cancer (GC) involves chemotherapy and immunotherapy, but these methods have limitations and may cause toxicity and damage to healthy cells. This review focuses on the use of nanoparticles to overcome these challenges. Researchers have reported using nanoparticles for improving imaging techniques, such as Magnetic Resonance Imaging (MRI), Computed Tomography (CT), and Single-photon emission computed tomography (SPECT) by eliminating limitations like adverse reactions, low pharmacokinetics, rapid clearance, and non-specific distribution. Nanoparticles have also been used in chemotherapy to target specific cancerous cells, minimize side effects, improve drug effectiveness, protect therapeutic compounds from the body's harsh environment, and deliver multiple diagnostic and therapeutic agents simultaneously. Nanoparticles have also shown promise as a delivery platform for gene therapy in the treatment of GC, specifically using small interfering RNAs (siRNA) to inhibit the expression of specific genes driving the growth and proliferation of cancer cells using plasmid DNA to express specific proteins. The use of nanoparticles in oxidation therapy to deliver reactive oxygen species agents (ROS) has shown promise as a means of selectively targeting cancer cells while minimizing the toxicity to normal cells. Nanoparticles have also shown similar promise in the delivery of phytochemicals such epigallocatechin gallate (EGCG) in cancer treatment. The biostability of nanoparticles, and their ability to precisely target cancer cells has provided a method for stable systemic delivery of drugs, improved the effectiveness of GC diagnosis, treatment modalities, and prognosis, and has shown tremendous potential to further improve outcomes for patients with GC.
Downloads
References or Bibliography
Correa, P. (2013). Gastric Cancer. Overview. In Gastroenterology Clinics of North America (Vol. 42, Issue 2, pp. 211–217). https://doi.org/10.1016/j.gtc.2013.01.002.
Yada, T., Yokoi, C., & Uemura, N. (2013). The current state of diagnosis and treatment for early gastric cancer. Diagnostic and therapeutic endoscopy, 2013, 241320. https://doi.org/10.1155/2013/241320.
Nagaraju, G. P., Srivani, G., Dariya, B., Chalikonda, G., Farran, B., Behera, S. K., Alam, A., & Kamal, M. A. (2021). Nanoparticles guided drug delivery and imaging in gastric cancer. In Seminars in Cancer Biology (Vol. 69, pp. 69–76). Academic Press. https://doi.org/10.1016/j.semcancer.2020.01.006.
Nakamura, Y., Mochida, A., Choyke, P. L., & Kobayashi, H. (2016). Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer? Bioconjugate chemistry, 27(10), 2225–2238. https://doi.org/10.1021/acs.bioconjchem.6b00437.
Salapa, J., Bushman, A., Lowe, K., & Irudayaraj, J. (2020). Nano drug delivery systems in upper gastrointestinal cancer therapy. Nano Convergence, 7(1), 1-17.
Lin, M., Yao, W., Xiao, Y., Dong, Z., Huang, W., Zhang, F., Zhou, X., & Liang, M. (2021). Resveratrol-modified mesoporous silica nanoparticle for tumor-targeted therapy of gastric cancer. Bioengineered, 12(1), 6343–6353. https://doi.org/10.1080/21655979.2021.1971507Author 1, A.B. Title of Thesis. Level of Thesis, Degree-Granting University, Location of University, Date of Completion.
Huang, X., El-Sayed, I. H., Qian, W., & El-Sayed, M. A. (2006). Cancer Cell Imaging and Photothermal Therapy in the Near-Infrared Region by Using Gold Nanorods. Journal of the American Chemical Society, 128(6), 2115–2120. https://doi.org/10.1021/ja057254a.
Zhang, K., Du, X., Yu, K., Zhang, K., & Zhou, Y. (2018). Application of novel targeting nanoparticles contrast agent combined with contrast-enhanced computed tomography during screening for early phase gastric carcinoma. Experimental and therapeutic medicine, 15(1), 47–54. https://doi.org/10.3892/etm.2017.5388.
Cheng, C. C., Huang, C. F., Ho, A. S., Peng, C. L., Chang, C. C., Mai, F. der, Chen, L. Y., Luo, T. Y., & Chang, J. (2013). Novel targeted nuclear imaging agent for gastric cancer diagnosis: Glucose-regulated protein 78 binding peptide-guided 111In-labeled polymeric micelles. International Journal of Nanomedicine, 8, 1385–1391. https://doi.org/10.2147/IJN.S42003.
Wang, P., Qu, Y., Li, C., Yin, L., Shen, C., Chen, W., Yang, S., Bian, X., & Fang, D. (2015). Bio-functionalized dense-silica nanoparticles for MR/NIRF imaging of CD146 in gastric cancer. International journal of nanomedicine, 10, 749–763. https://doi.org/10.2147/IJN.S62837.
Zhang, H., Li, X., Ding, J., Xu, H., Dai, X., Hou, Z., Zhang, K., Sun, K., & Sun, W. (2013). Delivery of ursolic acid (UA) in polymeric nanoparticles effectively promotes the apoptosis of gastric cancer cells through enhanced inhibition of cyclooxygenase 2 (COX-2). International Journal of Pharmaceutics, 441(1–2), 261–268. https://doi.org/10.1016/j.ijpharm.2012.11.034.
Yang, F., Li, A., Liu, H., & Zhang, H. (2018). Gastric cancer combination therapy: synthesis of a hyaluronic acid and cisplatin containing lipid prodrug coloaded with sorafenib in a nanoparticulate system to exhibit enhanced anticancer efficacy and reduced toxicity. Drug design, development and therapy, 12, 3321–3333. https://doi.org/10.2147/DDDT.S176879.
Hani, U., Osmani, R. A. M., Yasmin, S., Gowda, B. H. J., Ather, H., Ansari, M. Y., Siddiqua, A., Ghazwani, M., Fatease, A. al, Alamri, A. H., Rahamathulla, M., Begum, M. Y., & Wahab, S. (2022). Novel Drug Delivery Systems as an Emerging Platform for Stomach Cancer Therapy. In Pharmaceutics (Vol. 14, Issue 8). MDPI. https://doi.org/10.3390/pharmaceutics14081576.
Vrána, D., Matzenauer, M., Neoral, Č., Aujeský, R., Vrba, R., Melichar, B., Rušarová, N., Bartoušková, M., & Jankowski, J. (2018). From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer. International Journal of Molecular Sciences, 20(1), 13. https://doi.org/10.3390/ijms20010013.
Zeng, D., Li, M., Zhou, R., Zhang, J., Sun, H., Shi, M., Bin, J., Liao, Y., Rao, J., & Liao, W. (2019). Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures. Cancer Immunology Research, 7(5), 737–750. https://doi.org/10.1158/2326-6066.CIR-18-0436.
Zhao, Q., Cao, L., Guan, L., Bie, L., Wang, S., Xie, B., Chen, X., Shen, X., & Cao, F. (2019). Immunotherapy for gastric cancer: dilemmas and prospect. Briefings in Functional Genomics, 18(2), 107–112. https://doi.org/10.1093/bfgp/ely019.
Coutzac, C., Pernot, S., Chaput, N., & Zaanan, A. (2019). Immunotherapy in advanced gastric cancer, is it the future? Critical Reviews in Oncology/Hematology, 133, 25–32. https://doi.org/10.1016/j.critrevonc.2018.10.007.
Kelly, R. J. (2017). Immunotherapy for Esophageal and Gastric Cancer. American Society of Clinical Oncology Educational Book, 37, 292–300. https://doi.org/10.1200/EDBK_175231.
Song, Z., Wu, Y., Yang, J., Yang, D., & Fang, X. (2017). Progress in the treatment of advanced gastric cancer. Tumor Biology, 39(7), 101042831771462. https://doi.org/10.1177/1010428317714626.
Gerson, J. N., Skariah, S., Denlinger, C. S., & Astsaturov, I. (2017). Perspectives of HER2-targeting in gastric and esophageal cancer. Expert Opinion on Investigational Drugs, 26(5), 531–540. https://doi.org/10.1080/13543784.2017.1315406.
Johnston, F. M., & Beckman, M. (2019). Updates on Management of Gastric Cancer. Current Oncology Reports, 21(8), 67. https://doi.org/10.1007/s11912-019-0820-4.
Ding, Y. N., Xue, M., Tang, Q. S., Wang, L. J., Ding, H. Y., Li, H., Gao, C. C., & Yu, W. P. (2022). Immunotherapy-based novel nanoparticles in the treatment of gastrointestinal cancer: Trends and challenges. World journal of gastroenterology, 28(37), 5403–5419. https://doi.org/10.3748/wjg.v28.i37.5403.
Yanes, R. E., Lu, J., & Tamanoi, F. (2012). Nanoparticle-based delivery of sirna and mirna for cancer therapy. In The Enzymes (Vol. 32, pp. 185-203). Academic Press. https://www.sciencedirect.com/bookseries/the-enzymes/vol/32/suppl/C.
Cui, D., Zhang, C., Liu, B., Shu, Y., Du, T., Shu, D., ... & Guo, P. (2015). Regression of gastric cancer by systemic injection of RNA nanoparticles carrying both ligand and siRNA. Scientific reports, 5(1), 1-14.
Wang, X., Hua, Y., Xu, G., Deng, S., Yang, D., & Gao, X. (2019). Targeting EZH2 for glioma therapy with a novel nanoparticle-siRNA complex. International journal of nanomedicine, 14, 2637–2653. https://doi.org/10.2147/IJN.S189871.
Avgustinovich, A. V., Bakina, O. V., Afanas' ev, S. G., Cheremisina, O. V., Spirina, L. V., Dobrodeev, A. Y., & Choynzonov, E. L. (2021). Nanoparticles in gastric cancer management. Current Pharmaceutical Design, 27(21), 2436-2444.
Asefi, Y., Fahimi, R., & Ghorbian, S. (2021). Synergistic Effect of Vitamin C with Superparamagnetic Iron Oxide Nanoparticles for Inhibiting Proliferation of Gastric Cancer Cells. Biointerfaces Res. Appl. Chem, 12, 3215-3224.
Granja, A., Pinheiro, M., & Reis, S. (2016). Epigallocatechin Gallate Nano delivery Systems for Cancer Therapy. Nutrients, 8(5), 307. https://doi.org/10.3390/nu8050307.
Tsai, W. H., Yu, K. H., Huang, Y. C., & Lee, C. I. (2018). EGFR-targeted photodynamic therapy by curcumin-encapsulated chitosan/TPP nanoparticles. International journal of nanomedicine, 13, 903–916. https://doi.org/10.2147/IJN.S148305.
Annaji, M., Poudel, I., Boddu, S. H. S., Arnold, R. D., Tiwari, A. K., & Babu, R. J. (2021). Resveratrol-loaded nanomedicines for cancer applications. Cancer reports (Hoboken, N.J.), 4(3), e1353. https://doi.org/10.1002/cnr2.1353.
Wang, Y., Liu, T., Zhang, E., Luo, S., Tan, X., & Shi, C. (2014). Preferential accumulation of the near infrared heptamethine dye IR-780 in the mitochondria of drug-resistant lung cancer cells. Biomaterials, 35(13), 4116-4124.
Yi, X., Yan, F., Wang, F., Qin, W., Wu, G., Yang, X., Shao, C., Chung, L. W., & Yuan, J. (2015). IR-780 dye for near-infrared fluorescence imaging in prostate cancer. Medical science monitor : international medical journal of experimental and clinical research, 21, 511–517. https://doi.org/10.12659/MSM.892437.
Yan, L., & Qiu, L. (2015). Indocyanine green targeted micelles with improved stability for near-infrared image-guided photothermal tumor therapy. Nanomedicine, 10(3), 361-373.
Shao, J., Liang, R., Ding, D., Zheng, X., Zhu, X., Hu, S., Wei, H., & Wei, B. (2021). A Smart Multifunctional Nanoparticle for Enhanced Near-Infrared Image-Guided Photothermal Therapy Against Gastric Cancer. International journal of nanomedicine, 16, 2897–2915. https://doi.org/10.2147/IJN.S289310.
Deng, L., Guo, W., Li, G., Hu, Y., & Zhang, L. M. (2019). Hydrophobic IR780 loaded sericin nanomicelles for phototherapy with enhanced antitumor efficiency. International journal of pharmaceutics, 566, 549-556.
ClinicalTrials.gov. Available online: https://clinicaltrials.gov (accessed on 18th March 2023).
Published
How to Cite
Issue
Section
Copyright (c) 2023 Dhroov Pathare; Dr. Salame Haddad
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
